Form FDA 483 (original) (raw)
The U.S. Food and Drug Administration (FDA) is authorized to perform inspections under the Federal Food, Drug, and Cosmetic Act, Sec. 704 (21 USC §374) "Factory Inspection". Form FDA 483, "Inspectional Observations," is a form used by the FDA to document and communicate concerns discovered during these inspections. Also referred to as "Form 483" or merely "483", it states thereon that it ... lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance
| Property | Value |
|---|---|
| dbo:abstract | The U.S. Food and Drug Administration (FDA) is authorized to perform inspections under the Federal Food, Drug, and Cosmetic Act, Sec. 704 (21 USC §374) "Factory Inspection". Form FDA 483, "Inspectional Observations," is a form used by the FDA to document and communicate concerns discovered during these inspections. Also referred to as "Form 483" or merely "483", it states thereon that it ... lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance A recipient of a 483 should respond to the FDA, addressing each item, indicating agreement and either providing a timeline for correction or requesting clarification of what the FDA requires. This response must be submitted within 15 business days regardless of the number of observations, as of September 2009. While a response is not compulsory, a good response can usually help a company avoid receiving a Warning Letter from the FDA, withholding of product approval, or plant shut-down. Most experts warn that responses should be comprehensive, well-reasoned, well-documented and timely, and that each observation should be addressed individually. The FDA encourages resolution of issues through informal mechanisms prior to the issuance of a 483. After issuance, manufacturers can use a formal two-tiered dispute resolution process described in the FDA document Guidance for Industry - Formal Dispute Resolution: Scientific and Technical Issues Related to Pharmaceutical CGMP,and they have 30 calendar days to do so. The FDA refers to cellular and tissue-based products as "human cells, tissue (biology), and cellular or tissue-based products" (HCT/Ps). To protect the health of consumers, the agency also inspects these facilities and documents observations on a 483. The authority to do so is granted by 21 CFR 1271 Subpart F. The U.S. FDA has jurisdiction only within the United States. However, the supply chain for pharmaceuticals often extends far beyond the boundaries of the U.S., so the agency has an interest in assuring that foreign operations part of the U.S. supply chain are in an appropriate state of control, even though they have no legal authority to do so — although they can restrict importation into the U.S. The agency therefore performs foreign inspections, and observations for these are also captured on a 483. Regardless of the local language, the 483 will be written in English. (en) |
| dbo:wikiPageExternalLink | https://www.fda.gov/ http://fdazilla.com/483s/list/ https://www.fda.gov/AboutFDA/CentersOffices/ORA/ORAElectronicReadingRoom/default.htm https://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/default.htm https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM070279.pdf |
| dbo:wikiPageID | 26833305 (xsd:integer) |
| dbo:wikiPageLength | 16634 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1124398632 (xsd:integer) |
| dbo:wikiPageWikiLink | dbr:FDA_Warning_Letter dbr:Bias dbc:United_States_government_forms dbr:Freedom_of_Information_Act_(United_States) dbr:Corrective_and_preventive_action dbr:Regulatory dbr:Dispute_resolution dbr:Header_(computing) dbr:21_CFR dbr:Federal_Food,_Drug,_and_Cosmetic_Act dbr:Food_and_Drug_Administration dbr:Timeline dbc:Food_and_Drug_Administration dbr:Tissue_(biology) dbr:Business_process dbr:Supply_chain dbr:Sanitization_(classified_information) dbr:United_States_Code dbr:Fiscal_year dbr:Human_cells dbr:CDER |
| dbp:wikiPageUsesTemplate | dbt:Lead_rewrite dbt:Reflist |
| dcterms:subject | dbc:United_States_government_forms dbc:Food_and_Drug_Administration |
| rdf:type | yago:WikicatUnitedStatesGovernmentForms yago:Abstraction100002137 yago:Form106290637 yago:LanguageUnit106284225 yago:Part113809207 yago:Relation100031921 yago:Word106286395 |
| rdfs:comment | The U.S. Food and Drug Administration (FDA) is authorized to perform inspections under the Federal Food, Drug, and Cosmetic Act, Sec. 704 (21 USC §374) "Factory Inspection". Form FDA 483, "Inspectional Observations," is a form used by the FDA to document and communicate concerns discovered during these inspections. Also referred to as "Form 483" or merely "483", it states thereon that it ... lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance (en) |
| rdfs:label | Form FDA 483 (en) |
| owl:sameAs | freebase:Form FDA 483 yago-res:Form FDA 483 wikidata:Form FDA 483 https://global.dbpedia.org/id/4jh9H |
| prov:wasDerivedFrom | wikipedia-en:Form_FDA_483?oldid=1124398632&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Form_FDA_483 |
| is dbo:wikiPageRedirects of | dbr:FDA_483 dbr:Form_483 |
| is dbo:wikiPageWikiLink of | dbr:FDA_483 dbr:FDA_warning_letter dbr:Office_of_Global_Regulatory_Operations_and_Policy dbr:Form_483 |
| is foaf:primaryTopic of | wikipedia-en:Form_FDA_483 |